Executive Summary
A cluster of 24 8-K filings on January 13, 2026, reveals a surge in distressed financing activity among US small-cap companies, dominated by material definitive agreements (Item 1.01 in ~80% of filings), new financial obligations (Item 2.03 in ~40%), and equity dilutions via unregistered sales (Item 3.02 in ~30%), signaling widespread liquidity pressures. Two high-materiality delistings (Co-Diagnostics and Estrella Immunopharma) underscore acute distress in micro-caps, particularly biotech, while larger names like Delta Air Lines and Energy Transfer LP dilute the pattern but highlight cross-sector ripples. Portfolio implications include heightened volatility in small-cap indices, dilution drag on NAVs, and short opportunities amid opaque disclosures limiting transparency.
Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from January 11, 2026.
Investment Signals(4)
- ▲
Delisting notices and listing failures [BEARISH] - Co-Diagnostics, Inc. and Estrella Immunopharma, Inc.
- ▲
Widespread unregistered equity sales indicating dilution [BEARISH] - Lifeward Ltd., Pelthos Therapeutics, AVITA Medical, Dogwood Therapeutics, AB International Group, American Rebel Holdings, N2OFF, Scorpius Holdings, SKYX Platforms
- ▲
Cluster of new direct financial obligations [BEARISH] - Momentus Inc., Lifeward Ltd., Pelthos Therapeutics, AVITA Medical, AB International Group, Clearway Energy, Transportation & Logistics Systems, Scorpius Holdings
- ▲
Terminations of material agreements [BEARISH] - AVITA Medical, Dogwood Therapeutics, Unknown Company (AccNo: 0001213900-26-003905)
Risk Flags(4)
- [HIGH SYSTEMIC RISK]▼
Acute delisting risks eroding liquidity and investor confidence in micro-caps
- [PORTFOLIO RISK]▼
Cumulative dilution from equity issuances across 9+ filings threatening shareholder value in small-cap portfolios
- [ASSESSMENT RISK]▼
Opacity in ~90% of filings due to undisclosed terms/values amplifying uncertainty and potential for adverse surprises
- [SECTOR RISK]▼
Biotech-heavy distress signals (7+ companies) pointing to sector-specific funding crunch amid tight capital markets
Opportunities(4)
- ◆
Short delisting candidates (Co-Diagnostics, Estrella) for immediate downside capture ahead of OTC transfers
- ◆
Avoid or hedge small-cap biotech/healthcare exposure (Lifeward, Pelthos, AVITA, Clene, Scorpius) amid dilution wave
- ◆
Monitor larger-cap agreements (Delta Air Lines, Energy Transfer LP) for non-distressed M&A alpha if exhibits reveal upside
- Portfolio rebalancing◆
Reduce small-cap tilt, rotate to cash/quality amid financing frenzy signals
Sector Themes(3)
- Biotech/healthcare distress financing frenzy◆
7+ filings (Pelthos, AVITA, Dogwood, Clene, Scorpius, Lifeward, Estrella) with debt/equity raises and delistings signaling capital scarcity
- Small-cap liquidity scramble◆
Cross-sector (tech, energy, logistics) pattern of Item 1.01/2.03/3.02 clusters indicating broad micro-cap funding distress
- Mixed signals in energy/transport◆
Larger players (Clearway, Energy Transfer, Delta, Transportation & Logistics) entering agreements amid smaller peers' turmoil, potential for divergent outcomes
Watch List(4)
- 👁
Co-Diagnostics, Inc. and Estrella Immunopharma, Inc. - Imminent delistings with high bearish materiality; track trading halts and OTC transitions
- 👁
Biotech cluster (Pelthos Therapeutics, AVITA Medical, Scorpius Holdings) - Monitor exhibit disclosures for dilution quantum and obligation terms post-filing
- 👁
Delta Air Lines, Inc. and Energy Transfer LP - Anomalous large-cap entries into material agreements; assess for distress vs. strategic deals via results (Item 2.02)
0001213900-26-003905) - High-risk disruption signal; identify company and track cascading impacts
Filing Analyses(24)
13-01-2026
Offerpad Solutions Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001193125-26-011046, Size: 466 KB), reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the agreement, transaction value, or financial impacts disclosed in the provided information.
13-01-2026
Momentus Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001140361-26-001016, Size: 365 KB), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), Item 3.03 (Material Modifications to Rights of Security Holders), and Item 9.01 (Financial Statements and Exhibits). No specific details on the agreement, transaction value, parties, dollar amounts, share counts, or other quantitative metrics are disclosed in the provided filing summary. Sector is not specified.
13-01-2026
DOMO, INC. filed a Form 8-K on January 13, 2026 (AccNo: 0001628280-26-001885, Size: 231 KB), reporting entry into a material definitive agreement (Item 1.01), departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements (Item 5.02), and financial statements and exhibits (Item 9.01). No specific details on the agreement, personnel involved, transaction terms, or financial impacts are provided in the summary. Sector is not specified.
13-01-2026
Delta Air Lines, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0000027904-26-000008, Size: 2 MB), reporting entry into a material definitive agreement (Item 1.01), results of operations and financial condition (Item 2.02), and financial statements and exhibits (Item 9.01). No specific details on the agreement, transaction value, financial metrics, or other quantitative data are disclosed in the provided filing summary. This is a multi-item mandatory filing under SEC 8-K requirements.
13-01-2026
Lifeward Ltd. filed a Form 8-K on January 13, 2026 (AccNo: 0001178913-26-000132, Size: 2 MB), reporting multiple events including entry into a material definitive agreement (Item 1.01), creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), unregistered sales of equity securities (Item 3.02), departures/elections/appointments of directors/officers or compensatory arrangements (Item 5.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No transaction values, share counts, financial metrics, named counterparties, people, or other quantitative details are disclosed in the provided filing summary. This is a multi-item mandatory disclosure.
13-01-2026
Pelthos Therapeutics Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001753926-26-000097, Size: 926 KB), reporting multiple items including Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing indicating a significant transaction likely involving financing or agreements, but no specific details, dollar values, parties, or impacts are disclosed in the provided summary. Sector is not specified.
13-01-2026
AVITA Medical, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001193125-26-011167), reporting multiple events including entry into a material definitive agreement (Item 1.01), termination of a material definitive agreement (Item 1.02), results of operations and financial condition (Item 2.02), creation of a direct financial obligation (Item 2.03), and unregistered sales of equity securities (Item 3.02), with exhibits in Item 9.01. This is a multi-item filing with no specific transaction values, financial metrics, or other quantitative details disclosed in the provided summary. Sector is not specified.
13-01-2026
Dogwood Therapeutics, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001104659-26-003211, Size: 1 MB), reporting entry into a material definitive agreement (Item 1.01), termination of a material definitive agreement (Item 1.02), unregistered sales of equity securities (Item 3.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific transaction details, values, counterparties, or financial metrics are disclosed in the provided summary. This is a multi-item mandatory filing as a material event.
13-01-2026
AB International Group Corp. filed a Form 8-K on January 13, 2026 (AccNo: 0001663577-26-000011, Size: 382 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), Item 3.02 (Unregistered Sales of Equity Securities), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory filing related to a core event involving a material agreement with financial and equity components. No specific transaction values, terms, or financial metrics are disclosed in the provided information.
13-01-2026
Co-Diagnostics, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001493152-26-001971, Size: 200 KB) under Item 3.01 announcing a notice of delisting or failure to satisfy a continued listing rule or standard; transfer of listing. No specific details on the delisting reason, transaction value, financial impacts, or other metrics are disclosed. Sector is not specified.
13-01-2026
AMERICAN REBEL HOLDINGS INC filed a Form 8-K on January 13, 2026 (AccNo: 0001493152-26-001991, Size: 2 MB), reporting multiple items including Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), Item 3.02 (Unregistered Sales of Equity Securities), Item 5.02 (Departure of Directors/Officers or Compensatory Arrangements), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction details, dollar values, share counts, or named entities disclosed in the provided summary. Sector not specified.
13-01-2026
Company (AccNo: 0001104659-26-003327) filed an 8-K on January 13, 2026, reporting entry into a Material Definitive Agreement under Item 1.01 and creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement under Item 2.03, with Financial Statements and Exhibits under Item 9.01. Event Type: Material Event. File size: 1 MB.
13-01-2026
Clearway Energy, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001104659-26-003322, Size: 1 MB), reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of the registrant. Item 9.01 discloses financial statements and exhibits. No details on transaction value, parties, terms, or financial metrics are provided in the summary.
13-01-2026
Greenlane Holdings, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001493152-26-002030, size 569 KB), reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No details on the agreement's terms, parties, value, or financial impacts are provided in the summary.
13-01-2026
N2OFF, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001493152-26-002031, Size: 344 KB), disclosing under Item 1.01 Entry into a Material Definitive Agreement, Item 3.02 Unregistered Sales of Equity Securities, and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction size, parties involved, or financial impacts are provided in the summary. Sector is not specified.
13-01-2026
Transportation & Logistics Systems, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001493152-26-002029, Size: 277 KB), disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. No specific details on the agreement, transaction value, counterparties, or financial impacts are provided in the filing summary. Sector is not specified.
13-01-2026
Company filed Form 8-K on January 13, 2026 (AccNo: 0001213900-26-003908, Size: 928 KB) reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. This is a Material Event disclosure from US SEC source. No details on the agreement's terms, parties, value, or financial impact are provided.
13-01-2026
The company filed a Form 8-K on January 13, 2026 (AccNo: 0001213900-26-003905), reporting the termination of a material definitive agreement under Item 1.02, with financial statements and exhibits under Item 9.01. This is classified as a Material Event from the US market, sourced from us_sec. No specific details on the agreement, transaction value, parties involved, or financial impacts are disclosed.
13-01-2026
Clene Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001437749-26-001196, Size: 965 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item mandatory filing for material events, but specific details of the agreement, events, or exhibits are NOT_DISCLOSED. No quantitative financial data, transaction values, or named counterparties are provided.
13-01-2026
The company filed a Form 8-K on January 13, 2026 (AccNo: 0001193125-26-011778, Size: 952 KB) disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, with exhibits under Item 9.01. This is a multi-item material event filing from the US SEC with no further details on transaction specifics, parties, or financial terms provided in the summary. Sector is not specified.
13-01-2026
Scorpius Holdings, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001079973-26-000077, Size: 388 KB), reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 3.02 unregistered sales of equity securities, and Item 9.01 financial statements and exhibits. This is a multi-item mandatory disclosure of material events. No transaction values, share counts, or other quantitative details are provided in the filing summary.
13-01-2026
Energy Transfer LP filed a Form 8-K on 2026-01-13 (AccNo: 0001193125-26-011876, Size: 513 KB) reporting Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. No details on the agreement, events, transaction value, or financial impacts are disclosed in the provided filing summary. Sector not specified.
13-01-2026
SKYX Platforms Corp. filed a Form 8-K on January 13, 2026 (AccNo: 0001493152-26-002076, Size: 385 KB), reporting under Item 1.01 entry into a material definitive agreement, Item 3.02 unregistered sales of equity securities, and Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific transaction details, dollar values, or financial metrics disclosed in the provided information. Sector is not specified.
13-01-2026
Estrella Immunopharma, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001213900-26-003998, Size: 241 KB), reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. This discloses a delisting event from the US market. Sector not specified.
Get daily alerts with 4 investment signals, 4 risk alerts, 4 opportunities and full AI analysis of all 24 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC